Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company’s plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. The announcement, made via press release, indicates that the FDA’s feedback is a crucial step in advancing the development of a seasonal immunopreventative for a disease that affects hundreds of thousands of Americans each year.
The planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons. The trial will evaluate the prevention of Lyme disease through six months after dosing, with manufacturing of the investigational product on track for delivery to study sites in the first quarter of 2027. TNX-4800 is being developed as two subcutaneous injections administered three months apart, with the potential to provide protection throughout the U.S. Lyme disease season.
Lyme disease is the most common vector-borne illness in the United States, with the Centers for Disease Control and Prevention estimating that approximately 476,000 Americans are diagnosed and treated for the disease each year. Current prevention methods rely primarily on avoiding tick bites and early antibiotic treatment, but a preventive antibody could offer a more reliable approach for individuals at high risk, such as those living in or traveling to endemic areas.
The significance of this FDA feedback lies in the potential to bring a new tool to the fight against Lyme disease. If successful, TNX-4800 could become the first immunopreventative for Lyme disease, filling a critical gap in public health. The adaptive trial design, which allows for modifications based on interim data, could expedite the development process while maintaining rigorous safety and efficacy standards.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) for fibromyalgia marked the first new treatment for the condition in over 15 years. In addition to its CNS portfolio, Tonix is advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The FDA’s support for the TNX-4800 study is a positive signal for the company’s immunology pipeline, which could diversify its revenue streams beyond CNS treatments. However, it is important to note that TNX-4800 and other product development candidates are investigational drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The news of the FDA feedback comes as Lyme disease cases continue to rise, partly due to climate change expanding tick habitats. A preventive antibody that offers season-long protection could significantly reduce the disease burden and healthcare costs associated with Lyme disease. The upcoming Phase 2 study will be closely watched by public health officials, clinicians, and patients alike.
For more information on Tonix Pharmaceuticals and its pipeline, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release can be found at https://ibn.fm/pe0eP.
